Article Text

PDF

L-dopa and carbidopa (sinemet) in the management of parkinsonism
  1. Edmund Critchley

    Abstract

    Parkinsonism is a degenerative disease. A weakening in the responsiveness to dopamine replacement therapy affects many patients: thus 45% fail to maintain their initial improvement after 2 years' and 50% after 3 years' medication. However, by reducing the peripheral and systemic side actions of dopamine through the selective introduction of sinemet, a decarboxylase inhibitor+L-dopa combination, a partial amelioration of as much as 35% at 2 years, or 20% at 3 years, can be achieved. There is evidence, also, that the initial choice of anti-parkinsonian therapy may be critical to the long term prognosis.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.